The FDA has granted full approval to Novavax's COVID-19 vaccine, but only for adults 65 and older, or those aged 12-64 with underlying health conditions. This is in contrast to Pfizer and Moderna's vaccines, which have broader approval. The FDA's decision, issued with unusual restrictions, comes ahead of a CDC advisory meeting on yearly COVID-19 vaccine recommendations. Novavax's CEO welcomed the approval, highlighting the vaccine's focus on high-risk groups. The FDA's decision prompted speculation about its reasons for imposing the restrictions, including the need for further studies on potential heart conditions and the vaccine's benefit in certain populations.

Prepared by Olivia Bennett and reviewed by editorial team.